XCancer

[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer

Description:

In this study, positron emission tomography (PET/CT) imaging will be used to evaluate sigma-2 (σ2) receptor activity in sites of primary breast cancer using the investigational radiotracer \[18F\]ISO-1.

Sponsor:

University of Pennsylvania

Phase:

Phase 1

Contacts:

Elizabeth McDonald, MD, PhD (PRINCIPAL_INVESTIGATOR)

David Mankoff, MD, PhD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT02284919 - Click here to see study on

ClinicalTrials.gov

ISO-1

Isotope(s):
Target(s):
  • PARP
Ligand Class: Small Molecules
Inclusion
  • Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures
  • 1. Adult patients, at least 18 years of age
  • Known or suspected breast cancer with at least one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast MRI)
Exclusion
  • Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
  • Inability to tolerate imaging procedure in the opinion of an investigator or treating physician
  • Unwilling or unable to provide informed consent.
  • 1. Females who are pregnant at the time of screening will not be eligible for this study, urine or serum pregnancy test will be performed in women of child-bearing potential at the time of screening.